Ether Oxygen Is Part Of The Chain Patents (Class 514/651)
-
Publication number: 20100196358Abstract: The present invention is related to a method and kit (or device) for the detection and/or the quantification of biomarkers related to tumorigenesis. Said method is advantageously used to propose or adapt an anti-tumoral therapeutic protocol to be administered to a subject. Furthermore, said method and kit (or device) are a technical platform for the identification of new compounds, which are preferably used at (a) specific step(s) of an anti-tumoral therapeutic protocol.Type: ApplicationFiled: February 16, 2006Publication date: August 5, 2010Applicant: Eppendorf Array Technologies S.A.Inventors: Veronique Mainfroid, Jose Remacle
-
Patent number: 7767717Abstract: The present invention provides a method for treating or preventing excessive scarring, including keloid and hypertrophic scars, by administering 4-hydroxy tamoxifen to a patient with excessive scarring or a wound at risk for developing excessive scarring.Type: GrantFiled: June 2, 2004Date of Patent: August 3, 2010Assignees: Ascend Therapeutics, Inc., Northwestern UniversityInventors: Andrew Palumbo, Julius Few, Dana Hilt
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Patent number: 7763603Abstract: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.Type: GrantFiled: August 9, 2007Date of Patent: July 27, 2010Inventors: Kimberly R. Tyeryar, Ashiwel S. Undie
-
Patent number: 7763752Abstract: An amino alcohol derivative represented by the following general formula (1) (for example, (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentane-1-ol) exhibits strong immunosuppressive effect while causing less side effects: .Type: GrantFiled: November 21, 2008Date of Patent: July 27, 2010Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Yasushi Kohno, Kiyoaki Tanaka, Kazuhiko Kuriyama
-
Publication number: 20100184861Abstract: The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules.Type: ApplicationFiled: October 16, 2009Publication date: July 22, 2010Inventors: Giovanni Politi, Erkki Heilakka
-
Publication number: 20100178353Abstract: The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability.Type: ApplicationFiled: March 24, 2010Publication date: July 15, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Naima MEZAACHE, Steven E. Frisbee, Patrick B. Woodall, Mark R. Herman
-
Publication number: 20100166674Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: ApplicationFiled: December 18, 2009Publication date: July 1, 2010Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20100168119Abstract: Methods and compositions are provided for preventing or reversing loss of the therapeutic effect of a drug, where the loss is associated with the repeated administration of the drug to a patient. The method includes administering to the patient a dopamine receptor agonist or partial agonist or a drug that increases the extracellular level of dopamine by enhancing release of dopamine, decreasing the removal of dopamine from the extracellular space, enhancing the synthesis of dopamine within the brain, or decreasing metabolic degradation of dopamine; and also administering to the patient an opioid receptor antagonist in an ultra-low dose amount, wherein the ultra-low dose amount is effective to prevent or reverse loss of therapeutic effects associated with the repeated administration of the drug to the patient. The methods are useful for various treatments, including treating Parkinson's Disease, Restless Leg Syndrome, depression, schizophrenia, psychostimulant drug abuse, or attention deficit disorder.Type: ApplicationFiled: October 21, 2009Publication date: July 1, 2010Applicant: PHARMORx, Inc.Inventors: David M. Bear, Robert M. Kessler
-
Publication number: 20100160294Abstract: A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine H1 agonist activity.Type: ApplicationFiled: December 14, 2009Publication date: June 24, 2010Inventors: Srinivas Rao, Jay Kranzler, Jeffery J. Anderson
-
Patent number: 7737185Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating wasting, especially a loss of muscle mass. The invention is also directed to methods for treating wasting in a patient with chronic obstructive pulmonary disorder. The present invention is also directed to methods for treating hypogonadism in males with chronic obstructive pulmonary disorder.Type: GrantFiled: May 17, 2007Date of Patent: June 15, 2010Assignee: Repros Therapeutics Inc.Inventors: Joseph S. Podolski, Ronald Wiehle
-
Methods and materials for determining pain sensitivity and predicting and treating related disorders
Publication number: 20100132058Abstract: Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided.Type: ApplicationFiled: July 25, 2005Publication date: May 27, 2010Inventors: Luda B. Diatchenko, William Maixner, Gary Slade, Andrea Gail Neeley -
Patent number: 7723392Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.Type: GrantFiled: August 6, 2008Date of Patent: May 25, 2010Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, Karl Reuter, Viktor Meier, Florian Stolz, Eliso Gogritchiani
-
Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
Patent number: 7718705Abstract: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.Type: GrantFiled: August 22, 2000Date of Patent: May 18, 2010Assignee: Eli Lilly and CompanyInventor: Karl Bruce Thor -
Publication number: 20100113606Abstract: The present invention relates to new aminopropanol modulators of beta-1 adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 3, 2009Publication date: May 6, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100105637Abstract: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be formulated into sustained-release pharmaceutical compositions.Type: ApplicationFiled: October 22, 2009Publication date: April 29, 2010Inventor: Cherng-ju Kim
-
Publication number: 20100099742Abstract: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis.Type: ApplicationFiled: November 30, 2009Publication date: April 22, 2010Inventors: Giorgio Stassi, Matilde Todaro
-
Publication number: 20100092453Abstract: A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile solvent system, and spray drying the system thus formed to provide porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof.Type: ApplicationFiled: July 24, 2009Publication date: April 15, 2010Inventors: Anne Marie Healy, Bernand McDonald, Owen I. Corrigan, Lidia Tajber
-
Publication number: 20100092454Abstract: What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin.Type: ApplicationFiled: December 20, 2007Publication date: April 15, 2010Inventors: Enrico De Vivo, Antonio Ponzetto, Chiara Cesano, Luisa Gennero, Gianfranco Merizzi, Emanuella Morra
-
Publication number: 20100093805Abstract: The present invention relates to a method of treating or alleviating the symptoms of amblyopia. It is based on the discovery that repeated administration of a specific drug, which is known to be clinically active to treat depression in humans, results in improved vision of the amblyopic eye.Type: ApplicationFiled: June 27, 2008Publication date: April 15, 2010Applicant: HERMO PHARMA OYInventors: Eero Castrén, Lamberto Maffei, Jose Maya Vetencourt
-
Publication number: 20100081720Abstract: The present application describes deuterium-enriched atomoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: December 4, 2009Publication date: April 1, 2010Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20100075969Abstract: The invention provides medicaments comprising an agent, which selectively modulates ?2-adrenergic receptor conformation, or receptor activity, or activation thereof. The medicaments may be used for treating diseases that are characterised by disorganized and/or abnormal vasculature, such as cancer and metastatic disease. The medicaments may also be used for promoting organized/normal branched vasculature.Type: ApplicationFiled: December 19, 2007Publication date: March 25, 2010Applicant: UNIVERSITY OF LEICESTERInventor: Christine Elaine Pullar
-
Publication number: 20100040690Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: ApplicationFiled: October 22, 2009Publication date: February 18, 2010Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Patent number: 7662815Abstract: The invention provides novel ?2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with ?2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 19, 2007Date of Patent: February 16, 2010Assignee: Theravance, Inc.Inventors: Robert Murray McKinnell, Edmund J. Moran
-
Patent number: 7662805Abstract: Oral antidepressant formulation comprising an effective antidepressant amount of at least one pharmaceutically acceptable antidepressant active agent and an effective amount lower than 50 mg of acetylsalicylic acid, derivatives of acetylsalicylic acid, or diaspirin, for reducing the onset of antidepressant action.Type: GrantFiled: December 6, 2004Date of Patent: February 16, 2010Inventors: Julien Mendlewicz, Philippe Kriwin, Roland Powis De Tenbossche
-
Publication number: 20100034902Abstract: The present invention provides methods for measuring, detecting, diagnosing, treating, and researching salt sensitivity and related conditions. In particular, the present invention provides methods for measuring, detecting, diagnosing, treating, and researching salt sensitivity through measuring aberrant red blood cell based potassium efflux levels. In addition, the present invention provides methods for treating conditions involving salt sensitivity (e.g., hypertension), preventing the onset of conditions involving salt sensitivity, identifying individuals at risk for developing salt sensitivity and related conditions, identifying new types of treatment for salt sensitivity and related conditions, and evaluating the effectiveness of treatments for conditions involving salt sensitivity (e.g., hypertension).Type: ApplicationFiled: January 17, 2008Publication date: February 11, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Maria Carolina Delgado, Bertram Pitt
-
Publication number: 20100029654Abstract: Methods and compositions for the treatment of Alzheimer's Disease are described. More specifically, the invention demonstrates that administration of cardiovascular agents to a mammal suffering from the symptoms of Alzheimer's Disease causes an amelioration of those symptoms. The finding of the present invention can be used in treatment regimens designed to attenuate or prevent Alzheimer's Disease.Type: ApplicationFiled: March 22, 2007Publication date: February 4, 2010Inventor: Giulio Pasinetti
-
Publication number: 20100009950Abstract: The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 29, 2009Publication date: January 14, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100009934Abstract: The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.Type: ApplicationFiled: June 8, 2009Publication date: January 14, 2010Applicant: CombinatoRx, IncorporatedInventors: Richard RICKLES, Margaret S. Lee
-
Publication number: 20090325999Abstract: This invention relates to personalized pharmaceutical kits, packaging, compositions, and methods for treatment of a mammal, comprising at least one antihistamine for treating an allergic disease or condition in a mammal, in combination with at least one wakefulness promoting agent for preventing sedative effects during day time use, while promoting the antihistamine and sedating effect during evening use.Type: ApplicationFiled: June 27, 2008Publication date: December 31, 2009Inventor: Jie Du
-
Publication number: 20090326607Abstract: An electrical stimulation method for the treatment of peripheral neuropathy is disclosed. In a preferred embodiment, the method utilizes an electrical stimulation device that includes a plurality of channels of electrodes each of which includes a first and second electrode positioned in electrical contact with tissue of a target region suffering from peripheral neuropathy. Agonist/antagonist muscles involved in abduction/adduction, flexion/extension, supination/pronation, protraction/retraction, and/or eversion/inversion in the peripheral body regions are stimulated with a patterned series of electrical pulses through channels of electrodes in accordance with a procedure for treating peripheral neuropathy.Type: ApplicationFiled: June 30, 2008Publication date: December 31, 2009Inventors: J. Chris Castel, Francis X. Palermo
-
Publication number: 20090298839Abstract: The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved method for genotype-based prescribing of beta-blockers in glaucoma management.Type: ApplicationFiled: May 29, 2009Publication date: December 3, 2009Inventors: Catherine Anne McCarty, James K. Burmester, Bickol N. Mukesh, Richard B. Patchett, Russell Alan Wilke
-
Patent number: 7625929Abstract: The invention relates to the compounds of general formula (I) where R1 represents H, a (C1-C4)alkyl, —CO(C1-C4)alkyl, (C1-C4)alkylphenyl or —CO-phenyl group, said phenyl being optionally substituted, R2 represents H, a halogen atom, an —S(O)zR3, —NHSO2R3, —NHSO2-phenyl or —NHSO2—(C1-C4)alkylphenyl group where z is equal to 0, 1 or 2 and where R3 represents a (C1-C4)alkyl group, said phenyl being optionally substituted; A is chosen from where n is equal to 0, 1 or 2, R4 and R5 represent H, a (C1-C4)alkyl, hydroxyl, cyano, phenyl, benzyl, piperidyl, —CONH2, —CO-phenyl, —COOR3, —CH(phenyl) (OH) and —C(phenyl)2(OH) group, or R4 and R5 form together an optionally substituted 6-membered aromatic ring, R6 represents H, a (C1-C4)alkyl, phenyl or benzyl group, and B represents a 5- or 6-membered nitrogen-containing heterocycle or homocycle optionally fused with a phenyl Group or optionally substituted; their addition salts; their method of preparation and their therapeutic application.Type: GrantFiled: May 26, 2003Date of Patent: December 1, 2009Assignee: sanofi-aventisInventors: Philippe R. Bovy, Roberto Cecchi, Tiziano Croci, Olivier Venier
-
Publication number: 20090291146Abstract: A process for producing lactose particles comprises combining a predetermined quantity of lactose seed particles to a first aqueous solution comprising a plurality of lactose particles to form a second solution, wherein the predetermined quantity of lactose seed particles is present in a well dispersed suspension and the first aqueous solution is saturated with said plurality of lactose particles; and subjecting the second solution to conditions sufficient to induce crystallization of the lactose seed particles to form a second plurality of lactose particles having a median particle size of about 25 microns to about 100 microns.Type: ApplicationFiled: August 8, 2007Publication date: November 26, 2009Inventors: Trevor Charles Roche, Marian Wladyslaw Wood-Kaczmar
-
Publication number: 20090286883Abstract: Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure.Type: ApplicationFiled: March 19, 2009Publication date: November 19, 2009Applicants: Universita' degli Studi di Padova (University of Padua)Inventors: Fabio DiLisa, Ning Feng, Nina Kaludercic, Nazareno Paolocci
-
Publication number: 20090281195Abstract: The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.Type: ApplicationFiled: September 19, 2008Publication date: November 12, 2009Applicant: S.S.C.I., INC.Inventor: Scott L. CHILDS
-
Publication number: 20090264470Abstract: The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.Type: ApplicationFiled: February 21, 2007Publication date: October 22, 2009Inventors: Teresa A. Bennett, James R. Hauske, Fu-Yue Zeng
-
Publication number: 20090238869Abstract: Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone or about 60:40 to about 75:25 of ethylcellulose:hydroxypropylmethylcellulose.Type: ApplicationFiled: June 2, 2009Publication date: September 24, 2009Inventor: Grant Heinicke
-
Publication number: 20090233941Abstract: This invention relates to co-crystals of at least one molecule of calyx[n]arene or at least one of its derivatives, and at least one biologically active molecule, compositions and medicines including them, and the use of these co-crystals and methods used to obtain them.Type: ApplicationFiled: April 18, 2007Publication date: September 17, 2009Applicants: Centre National de la Recherche Scientifique-CNRS, Universie' Claude Bernard de Lyon 1, Institute of Physical Chemistry-Polish Academy of SciencesInventors: Anthony William Coleman, Adina Nicoleta Lazar, Kinga Suwinska, Oksana Danylyuk
-
Publication number: 20090227682Abstract: The invention provides a xetine or salt thereof composition having a dissolution in a phosphate buffer at pH 6.8, using USP basket 10 Mesh at 75 rpm, of at least 15% at 60 minutes, of at least 40% at 120 minutes, of at least 70% at 300 minutes.Type: ApplicationFiled: March 4, 2008Publication date: September 10, 2009Applicant: Pharma PASS II LLCInventors: Benoit Schmitt, Laurent Imler
-
Publication number: 20090221658Abstract: The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.Type: ApplicationFiled: May 13, 2009Publication date: September 3, 2009Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Miodrag Radulovacki, David W. Carley
-
Publication number: 20090215907Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass, limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.Type: ApplicationFiled: March 17, 2006Publication date: August 27, 2009Inventor: Joseph S. Podolski
-
Publication number: 20090214643Abstract: Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists are formulated in a controlled-release formulation comprising: (1) a beta-adrenergic inverse agonist in a therapeutically effective quantity; and (2) at least one agent that controls release of the beta-adrenergic inverse agonist resulting in a pharmacokinetic profile that minimizes acute detrimental reduction in airway function with the first dose and with each successive dose. This pharmacokinetic profile typically results in slow release of the drug into the bloodstream resulting in a large average Tmax>4 hours. The controlled-release formulation may consist of multilayered matrix or erosional tablets, gastric-retention tablets, osmotic pump oral formulations, multiparticulate capsules or tablets or dermal patch.Type: ApplicationFiled: July 19, 2006Publication date: August 27, 2009Inventors: Amie E. Franklin, Michael Flashner, William J. Garner, David Wurtman, Richard A. Bond
-
Publication number: 20090215733Abstract: Methods of treating or reducing the risk of one or more effects or signs of induced hypogonadism after androgen or GnRH intake are disclosed herein. In an embodiment, a method of treating one or more effects after androgen or gonadotropin releasing hormone (GnRH) analogue intake comprises administering to a male subject at least one of a blocking compound which antagonizes estradiol binding to estradiol receptors or an inhibitor compound which inhibits endogenous production of estradiol, after androgen or gonadotropin releasing hormone (GnRH) analogue intake, to treat the one or more effects. The one or more effects include adverse body composition changes, decreased muscle strength, or both. The inhibitor compound and/or blocking compound may include antiestrogen agents, aromatase inhibitors, or combinations thereof.Type: ApplicationFiled: February 24, 2009Publication date: August 27, 2009Inventor: Michael Charles Scally
-
Publication number: 20090215906Abstract: Compositions comprising trans-clomiphene for treating male infertility may be used to treat male infertility.Type: ApplicationFiled: February 3, 2006Publication date: August 27, 2009Applicant: REPROS THERAPEUTICS INC.Inventor: Joseph S. Podolski
-
Publication number: 20090215738Abstract: Disclosed is a is a treatment for the adverse psychological effects (including depression, low self esteem, guilt, increased stress, anhedonia, decreased cognition, sleep disturbances, general fatigue, agitation/motor dyskinesia and decreased appetite) resulting from androgens or GnRH analogue intake, by administering a compound which antagonizes estradiol or its receptors, or blocks and prevents estradiol binding to the estradiol receptors (including antiestrogens) and/or a compound which inhibits endogenous production of estradiol, including aromatase inhibitors. Suitable antiestrogens include clomiphene and its isomer enclomiphene, tamoxifen, 4-hydroxytamoxifen, and toremifene. Suitable cytochrome P450 (P450arom) aromatase inhibitors include formestane, exemestane, anastrozole, and letrozole.Type: ApplicationFiled: February 24, 2009Publication date: August 27, 2009Inventor: Michael Charles Scally
-
Patent number: 7576103Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.Type: GrantFiled: December 21, 2005Date of Patent: August 18, 2009Assignee: Roche Palo Alto LLCInventors: Ralph New Harris, III, Nancy Elisabeth Krauss, James M. Kress, David Bruce Repke, Russell Stephen Stabler
-
Publication number: 20090202572Abstract: The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a ?-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of modulating bone mass and/or growth in a mammal by administering a composition of the present invention. In other aspects, the invention provides methods of modulating bone mass and/or growth in a mammal by administering a composition comprising a ?2-selective antagonist or agonist.Type: ApplicationFiled: May 13, 2006Publication date: August 13, 2009Inventors: Gerard Karsenty, Bruce Devens
-
Patent number: 7569729Abstract: Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an analytical method for analyzing the stability of Atomoxetine Hydrochloride are provided.Type: GrantFiled: April 5, 2006Date of Patent: August 4, 2009Assignee: Teva Pharmaceutical Fine Chemicals S.R.L.Inventors: Eugenio Castelli, Paolo Riva
-
Publication number: 20090192166Abstract: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.Type: ApplicationFiled: March 4, 2009Publication date: July 30, 2009Applicant: Duke UniversityInventors: Ranga R. Krishnan, Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinova, Tatiana D. Sotnikova